FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay

Kyle Blankenship

New Jersey’s Rocket Pharmaceuticals hit a major roadblock for its AAV-delivered gene therapy for heart failure in May after the FDA came asking for more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay

Kyle Blankenship

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Outlook's shares crash as wet AMD drug flunks Phase 3 test

FDA lifts clin­i­cal hold on Rock­et's gene ther­a­py for heart fail­ure af­ter 3-month de­lay

Kyle Blankenship

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Outlook's shares crash as wet AMD drug flunks Phase 3 test